-- FibroGenesis Advances Preclinical Data in Preparation for FDA
     Investigational New Drug Submission

FibroGenesis announced today new data supporting use of its PneumoBlast(TM) 
product in the battle against COVID-19. Using the widely accepted bleomycin 
model of lung scarring (fibrosis), Company scientists have demonstrated the 
administration and use of PneumoBlast(TM) induced a 51% reduction of lung 
fibrosis, which was statistically significant (p < .005).  Importantly, when 
PneumoBlast(TM) was compared head to head with bone marrow derived mesenchymal 
stem cells (BMSCs) for COVID-19, PneumoBlast(TM) was 221% more effective.  In 
producing the potent anti-inflammatory protein interleukin 1 receptor 
antagonist, which is believed to be the mechanism of scar tissue prevention by 
BMSC therapies currently in development, PneumoBlast(TM) was 192% more 
effective than BMSCs which was again, statistically significant (p < .005).

Logo - https://mma.prnewswire.com/media/1121989/FibroGenesis_Logo.jpg  

During an interview with Healthline.com, Dr. Lori Shah, transplant 
pulmonologist at New York-Presbyterian/Columbia University Irving Medical 
Center, stated "Holes in the lungs likely refers to an entity that has been 
dubbed 'post-COVID fibrosis,' otherwise known as post-ARDS [acute respiratory 
distress syndrome] fibrosis, which is irreversible and can result in severe 
functional limitations from patients, such as cough, shortness of breath, and 
need for oxygen." It has been reported that pulmonary fibrosis due to COVID-19 
is occurring in increasing numbers of patients in their 20s and 30s.

"COVID-19 represents a new clinical entity which not only causes death through 
lung inflammation, but in some patients causes permanent lung injury through 
stimulation of scarring," said Tom Ichim, Ph.D., Chief Scientific Officer of 
FibroGenesis. "The prospects that our cell therapy approach not only possesses 
therapeutic effects on animal models of the acute stage of COVID-19, but also 
benefits the long-term pathology, has our research team extremely excited."

"As the scientific and medical community is discovering more about the 
biological and medical consequences of the COVID-19 infection, FibroGenesis is 
eager to contribute to the therapeutic cure options currently being created to 
fight this global war against an invisible enemy," commented Pete O'Heeron, 
President/CEO of FibroGenesis. "While we are excited about potential vaccines 
in the pipeline, the fact remains that there are 3.8 million confirmed cases of 
COVID-19 in the U.S. and we do not know what the long-term outcomes for these 
patients will be.  To our knowledge, we are the only cell therapy company which 
is creating a therapy to resolve the initial pathology of infection and also 
proactively tackling its long-term consequences."

About FibroGenesis

Based in Houston, Texas, FibroGenesis, is a regenerative medicine company 
developing an innovative solution for chronic disease treatment using human 
dermal fibroblasts. Currently, FibroGenesis holds 235+ U.S. and international 
issued patents/patents pending across a variety of clinical pathways, including 
Disc Degeneration, Multiple Sclerosis, Parkinson's, Chronic Traumatic 
Encephalopathy, Cancer, Diabetes, Liver Failure, Colitis and Heart Failure. 
Funded entirely by angel investors, FibroGenesis represents the next generation 
of medical advancement in cell therapy. 

Visit www.Fibro-Genesis.com. 

SOURCE: FibroGenesis

CONTACT: Pete O'Heeron, CEO, Pete.OHeeron@Fibro-Genesis.com